乳がん治療薬の世界市場:モノクローナル抗体、ホルモン、化学療法、キナーゼ阻害剤、その他...市場調査レポートについてご紹介

【英文タイトル】Breast Cancer Drugs Market 2016-2026 : Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Breast Cancer Drugs Overview
1.2 Why you Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Breast Cancer and its Treatment
2.1 What is Breast Cancer?
2.2 The Second Most Common Cancer in the World
2.3 Normal Structure of the Human Breast
2.4 Classifying the Different Types of Breast Cancer
2.4.1 Pathology
2.4.2 Molecular Subtype
2.4.3 Stages
2.4.4 Grades
2.5 Treatment Protocols
2.5.1 Treatment Options for Localised Disease
2.5.1.1 The Different Types of Therapy for Localised Breast Cancer
2.5.1.2 Stage 0 – Lobular Carcinoma in Situ (LCIS) and Ductal Carcinoma in Situ (DCIS)
2.5.1.3 Adjuvant Chemotherapy and Adjuvant Hormonal Therapy Treatment Options for Stage 1-3 Localised Disease
2.5.2 Treatment Options for Recurrent or Metastatic Disease

3. Leading Breast Cancer Drugs
3.1 Herceptin (trastuzumab) by Roche: The Leading Breast Cancer Drug
3.1.1 Approved Indications: Breast Cancer is the Main Indication
3.1.2 Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
3.1.3 Total Herceptin Revenues 2010-2015
3.1.4 The Threat of Biosimilars
3.1.4.1 Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
3.1.4.2 Herzuma (Celltrion)
3.1.4.3 Total Biosimilar Trastuzumab Revenue Forecast, for all Indications, 2016-2026
3.1.5 Herceptin for Breast Cancer Revenue Forecast 2016-2026
3.2 Perjeta (pertuzumab) by Roche
3.2.1 Is a Recent Addition to the Market, Approved for Different Stages of Breast Cancer
3.2.2 Positive Results from Different Clinical Trials
3.2.3 Total Perjeta Revenues 2012-2015
3.2.4 Perjeta for Breast Cancer Revenue Forecast 2016-2026
3.3 Afinitor (everolimus) by Novartis
3.3.1 Multiple Approved Indications but Breast Cancer Leads
3.3.2 No Extension to HER2 Positive Breast Cancer, as Afinitor Fails to Meet Primary Objective in Phase 3 Trial
3.3.3 NICE Rejects Afinitor on Cost Basis, although Drug Remains on the Cancer Drugs Fund, Despite Rumours it Would be Removed
3.3.4 Total Afinitor Revenues 2010-2015
3.3.5 Afinitor for Breast Cancer Revenue Forecast 2016-2026
3.4 Faslodex (fulvestrant) by AstraZeneca
3.4.1 Approved for Breast Cancer all the Way Back in 2002, Higher Dose Approved in 2010
3.4.2 Patent Dispute with Mylan
3.4.3 Total Faslodex Revenues 2010-2015
3.4.4 Faslodex for Breast Cancer Revenue Forecast 2016-2026
3.5 Ibrance (palbociclib) by Pfizer
3.5.1 Accelerated Approval on the Back of Promising Data
3.5.2 Has Already Been Used to Treat Over 15,000 Patients, MAA Filed in Europe
3.5.3 Total Ibrance Revenues Q1-Q4 2015
3.5.4 Ibrance for Breast Cancer Revenue Forecast 2016-2026
3.6 Avastin (bevacizumab) by Roche
3.6.1 Multiple Approved Indications, Still Approved for Breast Cancer in Major Markets, Except for the US
3.6.1.1 Why was the FDA-Breast Cancer Label Withdrawn?
3.6.2 Total Avastin Revenues 2010-2015
3.6.3 Avastin for Breast Cancer Revenue Forecast 2016-2026
3.6.4 No Biosimilars Approved yet, but Multiple Candidates in Clinical Trials
3.6.5 Total Biosimilar Bevacizumab Revenue Forecast, for all Indications, 2016-2026
3.7 Kadcyla (ado-trastuzumab emtansine) by Roche
3.7.1 The First Antibody-Drug Conjugate to be Approved for Breast Cancer
3.7.2 Mixed Results from Different Clinical Trials
3.7.3 Total Kadcyla Revenues 2013-2015
3.7.4 Kadcyla for Breast Cancer Revenue Forecast 2016-2026
3.8 Femara (letrozole) by Novartis
3.8.1 Hormone Therapy for Early Breast Cancer
3.8.2 Total Femara Revenues 2010-2025
3.8.3 Femara for Breast Cancer Revenue Forecast 2016-2026
3.9 Abraxane (paclitaxel Protein-Bound) by Celgene
3.9.1 Breast Cancer was the first of its Approved Indications
3.9.2 Total Abraxane Revenues 2010-2015
3.9.3 Abraxane for Breast Cancer Revenue Forecast 2016-2026

4. Breast Cancer Drugs R&D Pipeline 2016-2026
4.1 Roche: Not Content with Dominating Current Market, Already Grooming Future Leaders
4.1.1 Taselisib (GDC-0032 / RG7604)
4.1.1.1 Positive Results from Phase 1 Trial
4.1.2 Atezolizumab (MPDL3280A / RG7446)
4.1.2.1 Early Results in Triple-Negative Breast Cancer
4.1.3 Investigating Kadcyla and Perjeta in Wider Breast Cancer Indications
4.2 Novartis
4.2.1 Buparlisib (BKM120)
4.2.1.1 Early-Results for Buparlisib in Combination with Olaparib
4.2.2 Alpelisib (BYL719)
4.2.3 Ribociclib (LEE011)
4.2.3.1 Phase 1b Results in Combination with Femara
4.3 AstraZeneca
4.3.1 AZD5363
4.3.1.1 Well Tolerated and Yielding Partial Response in Early Results from 2013
4.3.2 MEDI-573 (In Partnership with MedImmune)
4.4 Abemaciclib (LY2835219) by Eli Lilly
4.4.1 Coveted Breakthrough Therapy Designation from the FDA
4.5 Veliparib (ABT-888) by AbbVie
4.6 Ganetespib by Synta Pharmaceuticals
4.7 Entinostat by Syndax Pharmaceuticals
4.7.1 Syndax Collaborating with Merck and Roche, Breakthrough Therapy Designation
4.8 Lucitanib by Clovis Oncology
4.9 Glembatumumab vedotin (CDX-011) by Celldex Therapeutics
4.9.1 Results from EMERGE Study
4.10 MM-302 by Merrimack
4.10.1 Phase 1 Results Released April 2015
4.11 Neratinib (PB272) by Puma Biotechnology
4.12 ENMD-2076 by CASI Pharmaceuticals
4.13 Margetuximab by MacroGenics

5. Global Breast Cancer Drugs Market 2016-2026
5.1 The Global Breast Cancer Drugs Market Forecast 2016-2026
5.2 What Factors will Drive Growth in the Global Breast Cancer Drugs Market?
5.3 Increasing Rate of Breast Cancer
5.3.1 What Factors are Contributing to this Increase?
5.4 Dynamic and Lucrative Sector with Strong R&D Pipeline
5.5 The Use of Combination Therapies Brings Various Benefits to Both Patients and Companies
5.6 What Factors will Restrain Growth in the Breast Cancer Drugs Market?
5.7 Patent Expiries for Key Drugs Will Open up Market to Generic and Biosimilar Competition
5.8 Declining Healthcare Budgets Lead to Cost Pressures
5.9 New Therapies that Only Offer Modest Benefits over Existing Treatments, and Intense Competition
5.10 SWOT Analysis of the Global Breast Cancer Drugs Market

6. Leading Therapeutic Segments and National Markets within the Global Breast Cancer Drugs Market
6.1 The Main Therapeutic Segments within the Breast Cancer Drugs Market, Forecast 2016-2026
6.1.1 Therapeutic Composition of the Market in 2015, 2020 and 2026
6.1.2 Monoclonal Antibodies (mAbs) Segment Forecast 2016-2026
6.1.3 Chemotherapy and Hormone Therapy Segment
6.1.4 Kinase Inhibitor Segment Forecast 2016-2026
6.1.5 ‘Other’ Segment Forecast 2016-2026
6.2 Leading National Markets for Breast Cancer Drugs
6.2.1 Leading Regional Markets for Breast Cancer, Forecast 2016-2026
6.2.2 Regional Composition of the Market in 2015, 2020 and 2026
6.2.3 US Breast Cancer Drugs Market 2016-2026
6.2.3.1 The Dominant National Market, and will Remain so Throughout the Forecast Period, Although is Undergoing Some Changes
6.2.3.2 US Breast Cancer Drugs Market Forecast 2016-2026
6.2.4 EU5 Breast Cancer Drugs Market 2016-2026
6.2.4.1 German Breast Cancer Drugs Market: The Leading EU Market, Undergoing Reforms
6.2.4.2 German Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.3 French Breast Cancer Drugs Market: Some Reduction in Healthcare Spending, but National Healthcare System Remains Strong
6.2.4.4 French Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.5 Italian Breast Cancer Drugs Market: Facing Challenges
6.2.4.6 Italian Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.7 UK Breast Cancer Drugs Market: Pricing is a Contentious Issue
6.2.4.8 UK Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.9 Spanish Breast Cancer Drugs Market
6.2.4.10 Spanish Breast Cancer Drugs Market Forecast 2016-2026
6.2.5 Japanese Breast Cancer Drugs Market
6.2.5.1 Rapidly Ageing Population will Boost the Market, but will a Successful Generic Market be Established?
6.2.5.2 Japanese Breast Cancer Drugs Market Forecast 2016-2026
6.2.6 BRIC Breast Cancer Drugs Market
6.2.6.1 Chinese Breast Cancer Drugs Market: Nation to Become one of the Major Global Players due to Rapid Growth
6.2.6.2 Chinese Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.3 Brazilian Breast Cancer Drugs Market: Healthcare in the Country is Taking Great Strides Forward
6.2.6.4 Brazilian Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.5 Russian Breast Cancer Drugs Market: Punches Below its Weight
6.2.6.6 Russian Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.7 Indian Breast Cancer Drugs Market: Generics are King
6.2.6.8 Indian Breast Cancer Drugs Market Forecast 2016-2026

7. Research Interviews
7.1 Interview with Dr Ken Ren, CEO of CASI Pharmaceuticals
7.1.1 On ENMD-2076 for Triple Negative Breast Cancer
7.1.2 Status of the Chinese Oncology Market
7.1.3 On the Properties that will Allow CASI to compete Against Giants in the Market, Such as Roche
7.1.4 On Drivers and Restraints for the Market
7.1.5 On the Challenges of Developing a Pipeline Product for the Breast Cancer Market, and Ways of Overcoming Them
7.2 Interview with MacroGenics
7.2.1 On Margetuximab for Metastatic Breast Cancer
7.2.2 On Where Margetuximab would fit into the Competitive HER2 Space
7.2.3 On the Challenges of Developing a Pipeline Product

8. Conclusions from Our Research and Analysis
8.1 How will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How will the Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks


【レポート販売概要】

■ タイトル:乳がん治療薬の世界市場:モノクローナル抗体、ホルモン、化学療法、キナーゼ阻害剤、その他
■ 英文:Breast Cancer Drugs Market 2016-2026 : Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals
■ 発行日:2016年3月
■ 調査会社:visiongain
■ 商品コード:VGAIN6041534
■ 調査対象地域:グローバル
  • 世界の無機酸類市場2015
    The Global Inorganic Acids Industry Report 2015 is a professional and in-depth study on the current state of the Inorganic Acids industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Inorganic Acids market analysis is provided for the international markets including development trends, competitive landsc …
  • Atripla (HIV):市場予測と分析(~2022)
    Atripla (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Atripla (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a dea …
  • Esophageal Cancer:グローバル臨床試験レビューH2, 2013
    Esophageal Cancer Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Esophageal Cancer Global Clinical Trials Review, H2, 2013" provides data on the Esophageal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Esophageal Cancer. It includes an overview of the trial numbers and their recruitment s …
  • 医療レポート:Uveitis-疫学予測(~2022)
    EpiCast Report: Uveitis - Epidemiology Forecast to 2022 Summary Uveitis is a serious eye condition that often results in permanent vision damage due to frequent recurrence even after treatment. It consists of a group of diseases that present with inflammation of the uvea, can occur in one or both eyes, and may also affect the adjacent tissues such as the retina, optic nerve, and vitreous humor. Sy …
  • グローバルにおける糖尿病網膜症治療市場(2014-2018)
    About DR and its Treatment Types DR is defined as an eye disorder that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye which acts as a film for the formation of an image. Long-term diabetes affects the retina as a high blood glucose level can deteriorate and damage the tiny blood vessels in the retina. DR is broadly classified into either non-pro …
  • 世界の質量分析市場動向及び予測(~2018)
    Over the years, the mass spectrometry market—comprising of instruments, consumables, and services—has witnessed various technological advancements. These advancements have led to a growth in the number of mass spectrometry applications. Some of the applications using mass spectrometry are drug discovery and development, metabolomics, biomarkers, and diagnostics. However, the high cost of instrumen …
  • スマートパーキングの世界市場予測(~2021年)
    “Increasing vehicle sales and limited parking availability are expected to fuel the demand for smart parking in passenger cars”The passenger car smart parking market is projected to grow at a CAGR of 17.94%, to reach a market size of USD 5.25 billion by 2021. Worldwide vehicle production has increased from 84.2 million in 2012 to 90.8 million in 2015. Furthermore since 2012, with a growth of 8.6%, …
  • 2014年戦略提言:アメリカのポイントオブケア(POC)血液凝固検査市場
    This new 418-page report from Venture Planning Group contains 42 tables, and provides a comprehensive analysis of the POC coagulation testing market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effect …
  • 乳製品代替食品の世界市場:豆乳、アーモンドミルク、ライスミルク
    The global dairy alternatives market has witnessed rise in demand for dairy-free food & beverage products from consumers who suffer from dairy allergies, lactose intolerance, and health conscious consumers. Globally, the rise in preference for vegan diet and growing health concerns has led to the large-scale adoption of dairy alternatives for various applications. The global market is projected to …
  • 医療機器セキュリティソリューションの世界市場予測・分析2020-2024
    Global Medical Device Security Solutions Market: About this market Technavio’s medical device security solutions market analysis considers sales from wearable and external medical devices, hospital medical devices, and internally embedded medical devices. Our study also finds the sales of medical device security solutions in APAC, Europe, MEA, North America, and South America. In 2018, the wearabl …
  • 東南アジアのデータセンタ建設市場2016-2020
    About Data Center Construction Market in South East Asia The construction of a data center encompasses design, architecture, installation of electrical and mechanical systems, and general construction works. The demand for cloud-based services and the growth of the Internet of Things (IoT) are prompting enterprises in Southeast Asia to construct data centers to gain a competitive edge. Complexitie …
  • H3N2感染(H3N2 Infection):治療薬開発パイプライン動向(2015年上半期版)
    H3N2 Infection - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘H3N2 Infection - Pipeline Review, H1 2015’, provides an overview of the H3N2 Infection’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action ( …
  • ペット用品の世界市場2015-2019
    Pet accessories are specialty products that are manufactured according to the functional requirements of pets such as dogs, cats, birds, small animals, and reptiles. These accessories include a variety of products such as feeding, bedding products, toys and leashes. These accessories are available in pet speciality stores and retail outlets such as supermarkets, hypermarkets, discounters globally. …
  • 世界における乳製品成分市場動向及び予測(~2018)
    The dairy ingredients market is experiencing new traction due to rise in the demand for protein-enriched diet foods and beverages among consumers. This report estimates the market value and volume of dairy ingredients by types and applications. In terms of geography, the report is segmented into Asia-Pacific, Europe, North America, and Rest of the World (ROW). The dairy ingredients market is broad …
  • 世界のマイクロ保険市場動向
    Timetric’s 'Insight Report: Microinsurance – Tapping an Unconventional Market' covers detailed analysis of the global microinsurance industry as a source of growth for insurers. It provides: • Insights into the key global market trends in the microinsurance industry. • Evaluation of microinsurance as a business case for commercial insurers. • Insights into different microinsurance business models. …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。